On September 1, 2020 Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, reported that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma will present at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Benitec Biopharma, SEP 1, 2020, https://www.prnewswire.com/news-releases/benitec-biopharma-to-present-at-hc-wainwrights-22nd-annual-global-investment-conference-301121597.html [SID1234564260]). The relevant details are outlined below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, September 16, 2020
Event: H.C. Wainwright 22nd Annual Global Investment Conference
Time: 11:30 A.M. EDT
Webcast Link: View Source

Please visit the link above to register for the presentation which will be presented via webcast during the virtual conference. The presentation will also be streamed on the Investor Relations section of the Company’s website, View Source, and a copy of the presentation will be released to Nasdaq and posted on the Company’s website at the above URL prior to the event.

If you would like to arrange a virtual 1×1 meeting with Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec after the presentation, please contact the Benitec IR Team using the details below.

On September 1, 2020 Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, reported that management will participate in four investor conferences in September (Press release, Eiger Biopharmaceuticals, SEP 1, 2020, View Source [SID1234564259]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 15th Annual BioPharma Conference. Eiger will participate in two panels:
"COVID-19 Therapeutics" on Wednesday, September 9, 9:50-10:20 AM ET
"Challenges and Opportunities in Rare Disease Drug Development" on Wednesday, September 9, 4:15-4:45 PM ET

Baird Global Healthcare Conference 2020. Eiger will present a corporate update on Wednesday, September 9, 12:50-1:20 PM ET.

H.C. Wainwright 22nd Annual Global Investment Conference from September 14- September 16.

Cantor Global Virtual Healthcare Conference 2020. Eiger will present a corporate update on Thursday, September 17, 2:00-2:30 PM ET.
Eiger will host one-on-one meetings at all conferences. Live webcasts of the Citi panels and Baird and Cantor presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the live event.

On September 1, 2020 Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, reported that D. Keith Grossman, Nevro’s Chairman, CEO and President, will present at the following conferences (Press release, Nevro, SEP 1, 2020, View Source [SID1234564258]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 2020 Virtual Healthcare Conference
Wednesday, Sept. 9, 2020 at 4:00 pm ET

Morgan Stanley 18th Annual Global Healthcare Conference
Monday, Sept. 14, 2020 at 3:00 pm ET

A live webcast of these events will be available on the Investors section of Nevro’s website at www.nevro.com. A webcast replay will be available approximately one hour after each live webcast ends and will be accessible for approximately 14 days.

On September 1, 2020 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, reported that it will webcast Management presentations as follows (Press release, Theravance, SEP 1, 2020, View Source [SID1234564257]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 18th Annual Global Healthcare Conference 2020 on Monday, September 14 at 1:30 p.m. ET (10:30 a.m. PT/5:30 p.m. GMT)
H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 9:30 a.m. ET (6:30 a.m. PT/1:30 p.m. GMT)
Webcasts of the presentations may be accessed by visiting the "Investors" section of Theravance Biopharma’s website at www.theravance.com under the "Presentations and Events" tab. Replays of the webcasts will be archived on the Company’s website for at least 30 days.

On September 1, 2020 Nordic Nanovector ASA (OSE: NANO) reported that its management team will present a corporate overview and host one-on-one meetings with investors at the Pareto Securities 11th Healthcare Conference, taking place 2nd-3rd September 2020 (Press release, Nordic Nanovector, SEP 1, 2020, View Source [SID1234564255]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will take place at 15:00hrs CEST on Thursday, 3rd September.

The company presentation will be available on Nordic Nanovector’s Investors and Media page at the same time.